Found: 18
Select item for more details and to access through your institution.
Prevention of Immune Cell Apoptosis as Potential Therapeutic Strategy for Severe Infections.
- Published in:
- Emerging Infectious Diseases, 2007, v. 13, n. 2, p. 191, doi. 10.3201/eid1302.060963
- By:
- Publication type:
- Article
Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Reply to Dunning.
- Published in:
- 2015
- By:
- Publication type:
- commentary
Correlates of Protection for Herpes Zoster Vaccine: Evaluating Candidate Immunological Variables.
- Published in:
- 2015
- By:
- Publication type:
- commentary
Fold Rise in Antibody Titers by Measured by Glycoprotein-Based Enzyme-Linked Immunosorbent Assay Is an Excellent Correlate of Protection for a Herpes Zoster Vaccine, Demonstrated via the Vaccine Efficacy Curve.
- Published in:
- Journal of Infectious Diseases, 2014, v. 210, n. 10, p. 1573, doi. 10.1093/infdis/jiu279
- By:
- Publication type:
- Article
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Varicella-Zoster Virus–Specific Antibody Responses in 50–59-Year-Old Recipients of Zoster Vaccine.
- Published in:
- Journal of Infectious Diseases, 2013, v. 208, n. 9, p. 1386, doi. 10.1093/infdis/jit342
- By:
- Publication type:
- Article
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 8, p. e2225411, doi. 10.1001/jamanetworkopen.2022.25411
- By:
- Publication type:
- Article
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 8, p. 1, doi. 10.1001/jamanetworkopen.2022.25411
- By:
- Publication type:
- Article
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
- Published in:
- Rheumatology, 2019, v. 58, n. 5, p. 849, doi. 10.1093/rheumatology/key361
- By:
- Publication type:
- Article
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
- Published in:
- Rheumatology, 2018, v. 57, n. 8, p. 1423, doi. 10.1093/rheumatology/key121
- By:
- Publication type:
- Article
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 1, p. e380, doi. 10.1093/cid/ciac153
- By:
- Publication type:
- Article
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
- Published in:
- Clinical Infectious Diseases, 2017, v. 65, n. 7, p. 1174, doi. 10.1093/cid/cix484
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 1, p. 90, doi. 10.1002/jcph.1703
- By:
- Publication type:
- Article
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs.
- Published in:
- Rheumatology & Therapy, 2019, v. 6, n. 3, p. 339, doi. 10.1007/s40744-019-0157-3
- By:
- Publication type:
- Article
Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis.
- Published in:
- Rheumatology & Therapy, 2018, v. 5, n. 1, p. 231, doi. 10.1007/s40744-017-0090-2
- By:
- Publication type:
- Article
Reply to Arroyo.
- Published in:
- 2012
- By:
- Publication type:
- Letter
Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years.
- Published in:
- Clinical Infectious Diseases, 2012, v. 54, n. 7, p. 922, doi. 10.1093/cid/cir970
- By:
- Publication type:
- Article